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Abstract
A major challenge for cellular and molecular MRI is to study interactions between two different
cell populations or biological processes. We studied the possibility to simultaneously image
contrast agents based on two different MRI contrast mechanisms: chemical exchange saturation
transfer (CEST) and enhancement of T2 relaxation. Various amounts of superparamagnetic iron
oxide (SPIO) nanoparticles were mixed with a fixed concentration (250 μM) of the CEST agent
poly-L-lysine. T2 maps, CEST maps, and frequency-dependent saturation spectra were then
measured. Color-coded overlay maps demonstrated the feasibility of concurrent dual contrast
enhancement. We found that at concentrations lower than 5 μg(Fe)/ml both contrast agents can be
imaged simultaneously. At higher concentrations the iron-based agent can be used to “shut off”
the signal arising from the CEST agent. These initial findings are a first step towards using dual
CEST/T2 contrast imaging for studying multiple cellular or molecular targets simultaneously in
vivo.
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Introduction
Recently, a new type of MRI contrast has been developed that relies on selective labeling of
protons on contrast agents using a radiofrequency (RF) saturation pulse followed by transfer
of saturation via exchange to bulk water, producing a fractional reduction in the water
signal. As a result, these agents are being referred to as chemical exchange saturation
transfer (CEST) contrast agents (1). A variety of organic (1–4) and organometallic (5–8)
compounds have a sufficient number of protons to be detected at low concentrations and
with suitable chemical exchange rates and chemical shifts to be selectively labeled.
CEST contrast agents have a major advantage in that they are switchable, i.e., the contrast is
detectable only when a saturation pulse is applied at the specific frequency where the
agent’s exchangeable protons resonate. Recently, its application has been demonstrated for
imaging of cells using an artificial lysine-rich protein (LRP) as CEST agent (9). The
switchable “on-off” property raises the possibility for CEST agents to coexist with T1 and
T2 contrast agents, potentially enabling simultaneously imaging and tracking of two
different targets such as two cell populations at the same location. Before such studies are
undertaken, however, the interactions between these two different contrast mechanisms
should be examined carefully.
Among the previously reported diamagnetic CEST contrast agents, Poly-L-Lysine (PLL) has
a high exchange rate as well as multiple exchangeable protons resulting in amplification of
contrast by several orders of magnitude (3). Our initial CEST reporter gene is designed
based on these properties of PLL (9) and can produce a relatively constant intracellular
concentration in cells independent of cell division. A different source of cellular contrast
(T2) may be obtained by using superparamagnetic agents, either by labeling with iron oxide
(SPIO) particles (10) or by overexpression of ferritin as an MRI reporter gene (11–13). In
order to assess the feasibility of using CEST and iron oxide-induced contrast
simultaneously, we conducted an in vitro study using both agents. The results show a range
of concentrations in which the two contrast agents can be used concurrently and
distinguished from each other.
Materials and Methods
A phantom composed of glass NMR tube, 5 mm in diameter, containing 5 inner capillaries
tubes, each with or without 250μM PLL, (MW 22 kDa, Sigma St. Louis, MO, USA) and
different concentrations of SPIO (Feridex, 0–50 μg Fe/ml) were imaged at 11.7 T using a
Bruker MR spectrometer (using the software Paravision 3.0.2). For T2 measurements, a
spin-echo sequence was used (TR=3000 ms, TE=9.2, 20, 30, 40, 50, 60, 70, 80 and, 90 ms),
with a single scan being acquired for each echo time. CEST imaging was performed with the
parameters TR/TE=9000/6.35 ms, saturation power=0.5μT, saturation time=4000 ms, and
Δω=± 3.76 ppm from the water 1H frequency (to coincide with the PLL amide protons at
+3.76 ppm and for a control measurement at −3.76 ppm). A single 1 mm slice was acquired
with a field of view 5×5 mm and a matrix size of 32×32 pixels with an in plane resolution of
156 μm. The total voxel volume was 2.43×10−5 ml.
MR data were analyzed using MATLAB 5.6.1 (MathWorks). Maps of change in signal
intensity (MTRasym) were generated pixel by pixel from [[Sw−Δω −Sw+Δω]/Sw−Δω]×100,
where Sw−Δω and Sw+Δω are the average water signal intensities of 4 images acquired with a
saturation at Δω=±3.76 ppm from the water 1H frequency. T2 was determined from 1/R2
derived using a linear regression of log (MR signal) as function of TE.
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Theory
When using a spin echo imaging sequence with echo time, TE, the signal S without applying
a saturation pulse can be given by the following expression:
[1]
In this, the relaxation rates are given by
[2]
In which i=1,2 and  is the relaxivity.
CEST contrast is generally observed using the signal difference between two images, one
with the saturation pulse on resonance with the exchangeable peak, , and the second
with the saturation pulse on the opposite side of water, , with water being assigned to 0
ppm. The difference contrast or magnetization transfer ratio asymmetry (MTRasym) is then:
[3]
This expression is commonly related to the proton transfer ratio (PTR):
[4]
in which S0w is the signal without saturation and ksw is the contrast agent (solute)-water
exchange rate, xCA is the fractional concentration of exchangeable protons of the contrast
agent, tsat is the saturation time, α is the saturation efficiency, and the term kswxCA accounts
for back exchange of saturated water protons to the contrast agent, which will occur when
the exchange rates and/or the concentration of exchangeable protons for the CEST agent are
very high. This asymmetry analysis with respect to water partially corrects for direct
saturation effects that contribute to saturation and is not included in the PTR expression.
When studying the interaction between these two contrast agent types, direct saturation
becomes more important because the presence of a T2* agent will increase the direct
saturation contribution at the CEST agent frequency through broadening the water line. The
saturation factor α is determined as:
[5]
in which
[6]
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[7]
Thus, R1 and R2 contrast agents can affect the CEST effect through p and q.
Results
An MRI phantom was used in order to study the interactions between SPIO and CEST
contrast agents. Figure 1 shows a proton density image of the phantom and the
corresponding CEST and T2 maps. The change in signal intensity as a function of iron
concentration is summarized in Table 1. In the presence of 250 μM PLL and iron oxide
concentrations up to 0.5 μg Fe/ml, the MTRasym was found to be around 12%. One side
remark is that all samples contained PLL without iron oxide were placed in capillaries with a
thinner diameter which might led to susceptibility effects and lower MTRasym. At higher
iron concentrations (5 μg Fe/ml and above) the CEST contrast starts to drop. The frequency
dependent saturation spectrum (called Z-spectrum or CEST spectrum) in Fig. 2
demonstrates that higher Fe concentrations induce line broadening, which resulted in a
disappearance of the hallmark CEST “dip” in water intensity at the amide proton frequency.
The drop in CEST effect at high iron concentration is due to an increase in direct water
saturation at the exchangeable proton frequency.
As expected, the reduction in T2 shows a linear dependence (R2=0.92) on the iron
concentration indicating that this process is independent of the concurrent presence of PLL.
This finding is further supported by comparing the T2 values of two samples containing 0.5
μg(Fe)/ml with and without PLL (Table 1), where no significant difference was observed
between the two samples (unpaired 2-tailed t-Test, p=0.87).
A merged image of the R2 map and CEST map is shown in Fig. 3. From these results, it is
evident that the iron- and CEST-induced contrast can be distinguished from each other under
concurrent conditions.
Discussion
Combining CEST-labeling and SPIO-labeling may have potential applications in serial
studies that require simultaneous imaging of two cell populations. In the scenario of
different locations of cell injections, differential migration patterns may be visualized. In
addition, two cell populations may be identified separately when injected at the same
location but at two different time points. One such example is studying stem cell-tumor cell
interactions. Neural stem cells can exhibit extensive migration directed by trophic factors
secreted by glioma cells, offering new opportunities for drug delivery or homing of cells
expressing anti-tumor genes (14,15). Another example exists for interactions between
mesenchymal stem cells and certain immune cells (16). Techniques that allow labeling and
imaging of two cell types simultaneously may aid in optimizing cell therapies based on
tumor cell/stem cell interactions. As a first step, the present study has investigated the co-
existence of CEST and T2 contrast mechanisms and indicates a range of contrast agent
concentrations where such a dual labeling approach may be feasible.
In the phantom containing PLL and 0.5 μg Fe/ml, each voxel contains 12 pg of iron, which
is comparable to 1–2 labeled cells per voxel (17). It was found that this concentration does
not affect the CEST contrast. For a higher concentration of 5 μg Fe/ml, a reduction in the
CEST effect is observed from 11.9% to 10.3%. When extrapolated, this is proportional to
about 10–20 labeled cells. At 50 μg Fe/ml (proportional to 100–200 cells), an almost
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complete abolition of the CEST contrast was observed. Thus, assuming a total of about 20–
200 ×103 cells per voxel, if only 0.5% to 0.05% of the cells in a voxel are labeled (equal to
50 μg Fe/ml), there will be total elimination of the CEST contrast for this particular amide
proton based agent. Based on the in vitro measurements, our findings suggest that there is a
range of concentrations of PLL and iron oxide in which both contrast mechanisms can co-
exist. Nevertheless, a high number of SPIO-labeled cells may eliminate all CEST contrast.
Thus, regions rich in iron (such as liver or spleen) or tissues containing large number of
SPIO-labeled cells may potentially preclude the use of CEST agents. Recent studies have
used a similar principle of off-resonance saturation to detect the presence of SPIO in
phantoms (18) or iron deposits present in the brain (19). In both cases an off-resonance
saturation pulse was applied prior to signal acquisition. Since iron broadens the water line
the contrast will be increased as a result of direct saturation. However, if used properly, the
changes in CEST contrast can be used as a sensor for the presence of SPIO particles and
SPIO-labeled cells. When SPIO-labeled cells are migrating, the arrival and accumulation at
the site containing CEST contrast (i.e. tissue containing LRP-labeled cells (9)) could be
verified by a reduction in the MTRasym. This approach can be considered to be analogous to
the Fluorescent Resonant Energy Transfer (FRET) imaging capabilities of fluorescent
reporter genes (20).
Another approach for multiple labeling of different cells for MRI relies purely on CEST
agents. Two PARACEST agents with different chemical shift values were used for labeling
of two cell populations and their distinction using MRI (21). A recent study by the same
group showed that manipulating the shape of liposomes containing PARACEST agents can
create differences in the chemical shift which, in turn, can be useful for differential labeling
of multiple targets (22). We have recently showed that certain polypeptides with different
exchangeable protons are distinguishable one from another in vitro with potential for
multiple labeling studies (23). MRI detection of two cell populations has been demonstrated
in vivo by labeling one cell population with SPIO as a T2 agent and the other one with
manganese oxide nanoparticles as a T1 agent. Both cell populations were detected and could
be distinguished from another within the same imaging plane (24).
In this study we have used high PLL:SPIO ratios in order to minimize the effect of direct
binding of the iron oxide particles to the PLL, which by itself may alter contrast through the
formation of larger complexes. It is known that aggregation of SPIO through (biological)
complexation shortens the T2 as compared to an equivalent concentration of uncomplexed
nanoparticles (25). Furthermore, it is important to keep in mind that, in vivo, the CEST
contrast agent concentration may be below the 12% baseline value of this study. It should,
however, be possible to detect CEST effects of one percent or higher, i.e. similar to the
magnitude of typical fMRI signal changes, by comparing the signal intensity with and
without saturation and the asymmetry of the saturation using statistical approaches.
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Figure 1. Phantom layout with the corresponding CEST and T2 maps
a) Proton density image of capillaries containing different iron concentrations (0–50 μg (Fe)/
ml) with or without the presence of 250 μM PLL. b) CEST map showing the MTRasym
calculated as the percent of signal change between RF irradiation at Δω=±3.76ppm. c) T2
map acquired for the same phantom. The figure is representative of three independent
experiments.
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Figure 2. Saturation spectra
mean relative signal intensities of the samples as a function of saturation frequency. The
reduction in the signal intensity at Δω=3.76ppm from the water 1H frequency at 0 ppm is a
specific CEST effect due to amide proton exchange in PLL. The increase in Fe
concentration broadens the water line and explains the elimination of this CEST effect at
higher iron concentrations.
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Figure 3. Concurrent dual MRI contrast
a) CEST (MTRasym) map. b) R2 (1/T2) map of the same phantom. c) overlay of the maps a
and b. The color-coded map shows that PLL and iron oxides can be distinguished from each
other at lower concentrations, at higher concentrations the SPIO can “switch off” the CEST
contrast.
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